FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine

References

• Mauricio IL, Gaunt MW, Stothard JR et al. Genetic typing and phylogeny of the Leishmania donovani complex by restriction analysis of PCR amplified gp63 intergenic regions. Parasitology122, 393–403 (2001).
   PubMed Web of Science ®Google Scholar
• Alvar J, Cañavate C, Gutiérrez-Solar B et al.Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol. Rev.10, 298–319 (1997).
   PubMed Web of Science ®Google Scholar
• Tesh R. Control of zoonotic visceral leishmaniasis. Is it time to change strategies? Am. J. Trop. Med. Hyg.52, 287–292 (1995).
   PubMed Web of Science ®Google Scholar
• Dye C. The logic of visceral leishmaniasis control. Am. J. Trop. Med. Hyg.55, 125–130 (1996).
   PubMed Web of Science ®Google Scholar
• Khalil EAG, El Hassan AM, Zijlstra EE et al. Autoclaved Leishmania major vaccine for prevention of viscral leishmaniasis: a randomised, doubled-blind, BCG-controlled trial in Sudan. Lancet356, 1565–1569 (2000).
   PubMed Web of Science ®Google Scholar
• Turco SJ. The lipophosphoglycan of Leishmania. Parasitol. Today4, 55–257 (1988).
   Google Scholar
• Etges R, Bouvier J, Bordier C. The major surface protein of Leishmania promastigotes is a protease. J. Biol. Chem.261, 9098–9101 (1986).
   PubMed Web of Science ®Google Scholar
• Späth GF, Lye LF, Segawa H et al. Persistence without pathology in phosphoglycan-deficient Leishmania major. Science301, 1241–1243 (2003).
   PubMed Web of Science ®Google Scholar
• Bouvier J, Schneider P, Etges R et al. Peptide substrate specificity of the membrane-bound metalloprotease of Leishmania. Biochemistry29, 10113–10119 (1990).
   PubMed Web of Science ®Google Scholar
• Russell DG, Wright SD. Complement receptor type 3 (CR3) binds to an Arg–Gly–Asp-containing region of the major surface glycoprotein, gp63, of Leishmania promastigotes. J. Exp. Med.168, 279–292 (1988).
   PubMed Web of Science ®Google Scholar
• Russell DG, Talamas-Rohana P, Zelechowski J. Antibodies raised against synthetic peptides from the Arg–Gly–Asp-containing region of the Leishmania surface protein gp63 cross-react with human C3 and interfere with gp63-mediated binding to macrophages. Infect. Immun.57, 630–632 (1989).
   Google Scholar
• Palatnik CB, Previato JO, Gorin PAJ, Mendonça-Previato L. Partial chemical characterization of the carbohydrate moieties in Leishmania adleri glycoconjugates. Mol. Biochem. Parasitol.14, 41–54 (1985).
   Google Scholar
• McConville MJ, Bacic A. A family of glycoinositol phospholipids from Leishmania major. Isolation, characterization and antigenicity. J. Biol. Chem.264, 757–766 (1989).
   PubMed Web of Science ®Google Scholar
• Palatnik CB, Previato JO, Gorin PAJ et al. Leptomonas samueli glycoconjugates. Comparison with Herpetomonas samuelpessoai. Comp. Biochem. Physiol.86, 593–599 (1987).
   Google Scholar
• Mendonça-Previato L, Gorin PA, Previato JO. Investigations on polysaccharide components of cells of Herpetomonas samuelpessoai grown on various media. Biochemistry18, 149–154 (1979).
   Google Scholar
• Palatnik CB, Borojevic R, Previato JO et al. Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate. Infect. Immun.57, 754–763 (1989).
   PubMedGoogle Scholar
• Wilson ME, Pearson RD. Evidence that Leishmania donovani utilizes a mannose receptor on human mononuclear phagocytes to establish intracellular parasitism. J. Immunol.136, 4681–4688 (1986).
   PubMed Web of Science ®Google Scholar
• Olafson RW, Wallis AE, Mc Master R. Structure studies and surface glycoproteins of Leishmania promastigotes: isolation, aminoacid composition and aminoterminal sequence studies. In: Host–Parasite Cellular and Molecular Interactions in Protozoal Infections In: NATO ASI Series (Volume H11). Chang KP, Sneary D (Eds). Springer, Berlin, Germany 149–156 (1987).
   Google Scholar
• Palatnik CB. Os glicoconjugados ligantes do receptor de interiorizaçåo para promastigotas de Leishmania donovani (LD 1S Sudan) em macrófagos peritoneais murinos, såo espécie-específicos. PhD Tesis. Universidad Federal do Rio de Janeiro, RJ, Brazil 34–50 (1989).
   Google Scholar
• Palatnik-de-Sousa CB, Dutra HS, Borojevic R. Leishmania donovani surface glycoproteins GP36, is the major immunogen component of the fucose mannose ligand (FML). Acta Trop.53, 59–72 (1993).
   PubMedGoogle Scholar
• Palatnik CB, Previato JO, Mendonça-Previato L et al. A new approach to phylogeny of Leishmania: species specificity of glycoconjugate ligands for promastigote internalization into murine macrophages. Parasitol. Res.76, 289–293 (1990).
   PubMedGoogle Scholar
• Bouvier J, Etges R, Bordier C. Identification of the promastigote surface protease in seven species of Leishmania. Mol. Biochem. Parasitol.24, 73–79 (1987).
   PubMedGoogle Scholar
• Palatnik-de-Sousa CB, Gomes EM, Paraguai de Souza E et al.Leishmania donovani: titration of antibodies to the fucose mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg.89, 390–393 (1995).
   PubMed Web of Science ®Google Scholar
• Borja Cabrera GP, da Silva VO, da Costa RT et al. The FML-ELISA assay in diagnosis and prognosis of canine visceral leishmaniasis. Am. J. Trop. Med.61, 296–301 (1999).
   Google Scholar
• Palatnik-de-Sousa CB, Gomes EM, Paraguai de Souza E et al. The FML (fucose mannose ligand) of Leishmania donovani. A new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar. Rev. Soc. Bras. Méd. Trop.29, 153–163 (1996).
   Google Scholar
• André R, Brumpt L, Dreyfus B et al. Leishmaniose cutanée, leishmaniose cutanée-ganglionnaire et kala-azar transfusionnel. Trop. Dis. Bull.55, 379–381 (1958).
   Google Scholar
• Cummins D, Amin S, Halil O et al. Visceral leishmaniasis after cardiac surgery. Arch. Dis. Child.72, 235–236 (1995).
   Google Scholar
• Cohen C, Corazza F, De Mol P et al. Leishmaniasis acquired in Belgium. Lancet338, 128 (1991).
   PubMed Web of Science ®Google Scholar
• Mauny, I, Blanchot I, Degeilh B et al. Visceral leishmaniasis in an infant in Brittany: discussion of the modes of transmission out of endemic zones. Pediatrie. Bucur.48, 237–239 (1993).
   Google Scholar
• Luz KG, Gomes EM, da Silva VO et al. Prevalence of anti-Leishmania donovani antibody among Brazilian blood donors and polytransfused hemodialyzed patients. Am. J. Trop. Med. Hyg.57, 168–171 (1997).
   Google Scholar
• Otero ACS, da Silva VO, Luz KG et al. Occurrence of Leishmania donovani DNA in seroreactive Brazilian blood donors. Am. J. Trop. Med. Hyg.62, 128–131 (2000).
   PubMed Web of Science ®Google Scholar
• Paraguai de Souza E, Borja Cabrera GP, Pereira TRD et al. Occurrence of Leishmania donovani DNA in bone marrow of FML-seroreactive Brazilian blood donors. Transfusion39, 117S (1999).
   Google Scholar
• Grogl M, Daugirda JM, Hoover DL et al. Survivability and infectivity of viscerotropic Leishmania tropica from Operation Desert Storm participants in human blood products maintained under blood bank conditions. Am. J. Trop. Med. Hyg.49, 308–315 (1993).
   PubMed Web of Science ®Google Scholar
• Paraguai de Souza E, Esteves Pereira AP, Soares Machado FC et al. Visceral leishmaniasis: circulating Leishmania donovani parasites in blood of infected hamsters. Acta Trop.80, 69–75 (2001).
   Google Scholar
• Le Fichoux I, Quaranta JF, Aufevre JP et al. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J. Clin. Microbiol.37, 1953–1957 (1999).
   PubMed Web of Science ®Google Scholar
• Riera C, Fisa R, López-Chejade P et al. Asymptomatic infection by Leishmania infantum in blood donors from the Balearic Islands (Spain). Transfusion18, (2008). (Epub ahead of print).
   Google Scholar
• Giger U, Oakley DA, Owens SD et al.Leishmania donovani transmission by packed RBC transfusion to anemic dogs in the United States. Transfusion42, 381–383 (2002).
   Google Scholar
• Dodd RY. Transmission of parasites by blood transfusion. Vox Sang.74, 161–163 (1998).
   Google Scholar
• Commission Directive 2004/33/EC of 22 March 2004. Implementing Directive 2002/98/EC of the European Parliament and of Council as regards certain technical requirements for blood and blood components. Off. J. Eur. Union L91, 25–39 (2004).
   Google Scholar
• Palatnik-de-Sousa CB, Melo LMB, Borja-Cabrera GP et al. Improving methods for epidemiological control of canine visceral leishmaniasis based on a mathematical model. Impact on the incidence of the canine and human disease. An. Acad. Bras.Cien.76, 583–593 (2004).
   Google Scholar
• Courtenay O, Quinnell RJ, Garcez LM et al. Infectiousness in a cohort of Brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J. Infect. Dis.186, 1314–1320 (2002).
   Google Scholar
• Machado Braga MD, Coelho ICB, Lima Pompeu M et al. Controle do calazar canino: comparação dos resultados de um programa de eliminação rápida de cães sororreagentes por ensaio imuno-enzimático com outro de eliminação tardia de cães sororreagentes por teste de imunofluorescência indireta de eluato de papel filtro. Rev. Soc. Bras. Med. Trop.31, 419–424 (1998).
   Google Scholar
• Palatnik de Sousa CB. What is the potential use of serological tools in diagnosis of human kala-azar? (Analysis of specificity, sensitivity and predictive values). Rev. Bras. Med. Trop.34, 55–57 (2002).
   Google Scholar
• Ministério da Saúde, Sec. de Vigilância em Saúde. Dep de Vigilância epidemiológica. In: Manual de vigilância e controle da leishmaniose visceral. Série A. Normas e Manuais Técnicos. Ministério da Saúde (Ed.). Brasília, Basil 20–27 (2003).
   Google Scholar
• Palatnik-de-Sousa CB. Vaccines for leishmaniasis in the fore coming 25 years. Review. Vaccine26, 1709–1724 (2008).
   PubMed Web of Science ®Google Scholar
• Mohebali M, Khamesipour A, Mobedi I et al. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran. Vaccine22, 4097–4100 (2004).
   PubMed Web of Science ®Google Scholar
• Genaro O, Pinto JA, Da Costa CA et al. Phase III randomized double blind clinical trial on the efficacy of a vaccine against canine visceral leishmaniasis in urban area of Montes Claros, MG, Brazil. Mem. Inst. Oswaldo Cruz91, 116 (1996).
   Google Scholar
• Orenstein WA, Bernier RH, Dondero TJ et al. Field evaluation of vaccine efficacy. Bull. WHO63, 1055–1068 (1985).
   PubMed Web of Science ®Google Scholar
• Goto H, Lindoso JAL. Immunity and immunosuppression in experimental visceral leishmaniasis. Braz. Med. J. Biol. Res.37, 615–623 (2004).
   PubMed Web of Science ®Google Scholar
• da Silva VO, Borja-Cabrera GP, Correia Pontes NN et al. A Phase III trial of Efficacy of the FML- vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine19, 1068–1081 (2001).
   Google Scholar
• Borja-Cabrera GP, Correia Pontes NN, da Silva VO et al. Long lasting protection against canine kala-azar using the FML–QuilA saponin vaccine in an endemic area of Brazil(São Gonçalo do Amarante). Vaccine20, 3277–3284 (2002).
   PubMed Web of Science ®Google Scholar
• Palatnik-de-Sousa CB, Paraguai de Souza E, Gomes EM et al. Experimental murine Leishmania donovani infection: immunoprotection by the fucose mannose ligand (FML). Braz. J. Med. Biol. Res.27, 547–551 (1994).
   Google Scholar
• Palatnik-de-Sousa CB, Paraguai de Souza E, Gomes EM et al. The FML vaccine (fucose–manosse ligand) protects hamsters from experimental kala-azar. Ciência e Cultura. J. Braz. Assoc. Adv. Sci.46, 290–296 (1994).
   Google Scholar
• Santos WR, Paraguai de Souza E, Palatnik M et al. Vaccination with the FML antigen (fucose mannose ligand ) of Leishmania donovani in the Swiss albino model. Vaccine17, 2554–2561 (1999).
   Google Scholar
• Santos WR, de Lima VMF, Paraguai de Souza E et al. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine21, 30–43 (2002).
   PubMed Web of Science ®Google Scholar
• Aguilar-Be I, Zardo RS, Paraguai de Souza E et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect. Immun.73, 812–819 (2005).
   PubMed Web of Science ®Google Scholar
• Souza LOP, Palatnik-de-Sousa CB. Cross-protective efficacy of the prophylactic VR1012-NH36 Leishmania donovani DNA vaccine against cutaneous leishmaniasis by leishmanai amazonensis. Presented at: Vaccine Congress: 25 Years of Publication. Amsterdam, The Netherlands, 9–11 December 2007.
   Google Scholar
• Oliveira-Freitas E, Casas CP, Borja-Cabrera GP et al. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Vaccine24, 3909–3920 (2006).
   PubMed Web of Science ®Google Scholar
• Mendes CO, Kauffman C, Mello Machado A et al. Analysis of the hemolytic effect and in vivo toxicity of Quillaja brasiliensis saponins in the formulation of FML-vaccine against visceral leishmaniasis in mice. Mem. Inst. Oswaldo Cruz95, 187 (2000).
   Google Scholar
• Russell DG. Immunity to leishmaniasis: what properties delineate a protective antigen? Ann. Inst. Pasteur. Immunol.138, 774–781 (1987).
   Google Scholar
• Liew FY. Cell mediated immunity in experimental cutaneous leishmaniasis. Parasitol. Today2, 264–270 (1986).
   Google Scholar
• Rodrigues MM, Mendonça-Previato L, Charlab R et al. The cellular immune response to a purified antigen from Leishmania mexicana subsp. amazonensis enhances the size of the leishmanial lesion on susceptible mice. Infect. Immun.55, 3142–3148 (1987).
   Google Scholar
• Bradley DJ, Kirkley K. Regulation of Leishmania population within the host. The variable course of Leishmania donovani infections in the mice. Clin. Exp. Immunol.30, 119–129 (1977).
   PubMed Web of Science ®Google Scholar
• Sharifi I, Fekri AR, Aflatonian MR et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet351, 1540–1543 (1998).
   PubMed Web of Science ®Google Scholar
• Momeni AZ, Jalayer T, Emamjomeh M et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine17, 466–472 (1999).
   PubMed Web of Science ®Google Scholar
• Mahmoudzadeh-Niknam H, Kiaei SS, Iravani D. Leishmania tropica infection, in comparison to Leishmania major, induces lower delayed type hypersensitivity in BALB/c mice. Korean J. Parasitol.45, 103–109 (2007).
   Google Scholar
• Convit J, Ulrich M, Fernández CT et al. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg.87, 444–448 (1993).
   Google Scholar
• Gamboa-León R, Paraguai de Souza E, Borja Cabrera GP et al. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of L. donovani. Vaccine24, 4863–4873 (2006).
   PubMed Web of Science ®Google Scholar
• Barral-Netto M, Reed SG, Sadigursky M et al. Specific immunization of mice against Leishmania mexicana amazonensis using solubilized promastigotes. Clin. Exp. Immunol.67, 11–19 (1987).
   Google Scholar
• Borja-Cabrera GP, Soares Machado, FC, Esteves AP et al. Vaccination against experimental canine kala-azar with the FML antigen of Leishmania donovani and Quil-A saponin.Mem. Inst. Oswaldo Cruz93(Suppl. 2), 288 (1998).
   Google Scholar
• Borja-Cabrera GP, Gonçalves da Costa S, Paraguai de Souza E et al. Protective effect of the FML+QuilA saponin vaccine against experimental canine kala-azar. Mem. Inst. Oswaldo Cruz94(Suppl. 2), 204 (1999).
   Google Scholar
• Rafati S, Nakhaee A, Taheri T et al. Protective vaccination against canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and type II of L. infantum. Vaccine23, 3716–3725 (2005).
   PubMed Web of Science ®Google Scholar
• Ramiro MJ, Zárate JJ, Hanke T et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime–boost regime using DNA vaccine and vaccinia recombinant vectors expressing LACK. Vaccine21, 2474–2484 (2003).
   PubMed Web of Science ®Google Scholar
• Atlet L, Francino O, Solano-Gallego L et al. Mapping and sequencing of the canine NRAMP1 gene and identification of mutations in leishmaniasis-susceptible dogs. Infect. Immun.70, 2763–2771 (2002).
   Google Scholar
• Quinnell RJ, Kennedy LJ, Barnes A et al. Suscepibility to visceral leishmaniasis in domestic dog is associated with MHC class II polymorphism. Immunogenetics55, 23–28 (2003).
   Google Scholar
• Schetters TPM, Kleuskens J, Scholtes N et al. Vaccination of dogs against Babesia canis infection using parasite antigens from in vitro culture. Paras. Immunol.14, 295–305 (1992).
   PubMed Web of Science ®Google Scholar
• UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). Guidelines for the evaluation of Plasmodium falciparum vaccines in populations exposed to natural infections. World Health Organization, Geneva, Switzerland, 1997.
   Google Scholar
• Lemesre JL, Holzmuller P, Gonçalves RB et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp–MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine25, 4223–4234 (2007).
   PubMed Web of Science ®Google Scholar
• Nogueira FS, Moreira MAB, Borja Cabrera GP et al. Leishmune® vaccine blocks the transmission of canine visceral leishmaniasis. Absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine23, 4805–4810 (2005).
   PubMedGoogle Scholar
• Keenan CM, Hendricks LD, Lightner L et al. Visceral leishmaniasis in the German shepherd dog. I. Infection, clinical disease, and clinical pathology. Vet. Pathol.21, 74–79 (1984).
   PubMed Web of Science ®Google Scholar
• Deplazes P, Smith NC, Arnold P et al. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Par. Immunol.17, 451–458 (1995).
   PubMedGoogle Scholar
• Nieto CG, Garcia Alonso M, Requena JM et al. Analysis of the humoral response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis. Vet. Immunol. Immunopathol.67, 117–130 (1999).
   Google Scholar
• Solano-Gallego L, Riera C, Roura X et al.Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment. Vet. Parasitol.96, 265–276 (2001).
   Google Scholar
• Mendes CO, Paraguai de Souza E, Borja-Cabrera GP et al. IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniasis. Vaccine21, 2589–2597 (2003).
   Google Scholar
• Santos FN, Borja-Cabrera GP, Miyashiro LM et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine. Vaccine25, 6176–6190 (2007).
   PubMed Web of Science ®Google Scholar
• Borja-Cabrera GP, Cruz Mendes A, Paraguai de Souza E et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine22, 2234–2243 (2004).
   PubMed Web of Science ®Google Scholar
• Vercammen F, Fernandez-Perez FJ, del Amo C et al. Follow-up of Leishmania infantum naturally infected dogs treated with allopurinol: immunofluorescence antibody test, ELISA and western blot. Acta Trop.84, 175–181 (2002).
   Google Scholar
• Fernandez-Perez FJ, Gomez-Munoz MT, Mendez S et al.Leishmania-specific lymphoproliferative responses and IgG1/IgG2 immunodetection patterns by western blot in asymptomatic, symptomatic and treated dogs. Acta Trop.86, 83–91 (2003).
   Google Scholar
• Reis AB, Teixeira-Carvalho A, Vale AM et al. Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi. Vet. Immunol. Immunopathol.112, 102–116 (2006).
   Google Scholar
• Day MJ. Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation. Vet. Parasitol.147, 2–8 (2007).
   PubMed Web of Science ®Google Scholar
• Santana DM, Paraguai de Souza E, Borja-Cabrera GP et al. Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis. Mol. Biochem. Parasitol.120, 315–319 (2002).
   Google Scholar
• Fujiwara RT, Vale AM, Franca da Silva JC et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet. Res.36, 827–838 (2005).
   PubMed Web of Science ®Google Scholar
• Andrade RA, Reis AB, Gontijo CM et al. Clinical value of anti-Leishmania (Leishmania) chagasi IgG titers detected by flow cytometry to distinguish infected from vaccinated dogs. Vet. Immunol. Immunopathol.116, 85–97 (2007).
   Google Scholar
• Andrade PP, Menz I, Servio E et al. Serologic discrimination between vaccinated and infected dogs in visceral leishmaniasis. Presented at: Vaccine Congress: Celebrating 25 Years of Publication. Amsterdam, The Netherlands, 9–11 December 2007.
   Google Scholar
• Bhatia A, Daifalla NS, Jen S et al. Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol. Biochem. Parasitol.102, 249–261 (1999).
   PubMed Web of Science ®Google Scholar
• Badaró R, Benson D, Eulálio MC et al. rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J. Infect. Dis.173, 758–761 (1996).
   PubMed Web of Science ®Google Scholar
• Borja Cabrera GP, Santos FN, Paraguai de Souza E et al. Phase I safety and immunogenicity trial of Leishmune® in dogs of Brazilian endemic areas. Presented at: Third World Congress on Leishmaniosis (Worldleish III). Palermo, Italy, 10–15 April 2005.
   Google Scholar
• Parra LE, Borja-Cabrera GP, Santos FN et al. Safety trial using the Leishmune® vaccine against canine visceral leishmaniasis in Brazil. Vaccine25, 2180–2186 (2007).
   PubMedGoogle Scholar
• Rodrigues PN, Borja-Cabrera GP, Paraguai de Souza E et al. FML- vaccine formulation with increasing saponin concentrations in the Balb/c murine model. Rev. Inst. Med. Trop. SP.44, 132 (2002).
   Google Scholar
• Lemesre JL, Holzmuller P, Cavaleyra M et al. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine23, 2825–2840 (2005).
   PubMed Web of Science ®Google Scholar
• Moreno J, Nieto J, Masina S et al. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine25, 5290–300 (2007).
   Google Scholar
• Molano I, Alonso MG, Mirón C et al.Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet. Immunol. Immunopathol.92, 1–13 (2003).
   PubMed Web of Science ®Google Scholar
• Gradoni L, Foglia Manzillo V, Pagano A et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected. Vaccine23, 5245–5251 (2005).
   PubMed Web of Science ®Google Scholar
• UNDP/World Bank/WHO. Special Programme for Research and Training in Tropical Diseases (TDR). Malaria transmission blocking vaccines: an ideal public good. UNDP/World Bank/WHO. Special Programme for Research and Training in Tropical Diseases (TDR). TDR/RBM/MAL/VAC/2000.1 (consulted on 5 February, 2008)
   Google Scholar
• Ingonga P, Mbati PA, Anjili CO et al. The effect of immune sera from hamsters immunized with sandfly gut and whole body extract antigens on fecundity and mortality of Phlebotomus duboscqi. Acta Trop.60, 269–279 (1996).
   Google Scholar
• Mbati PA, Anjili CO, Odongo S et al.Leishmania major infections in Phlebotomus duboscqi fed on murine models immunized with L. major subcellular antigens and sandfly gut antigens. Onderstepoort. J. Vet. Res.67, 57–63 (2000).
   Google Scholar
• Tonui WK, Mbati PA, Anjili CO et al. Transmission blocking vaccine studies in leishmaniasis: I. Lipophosphoglycan is a promising transmission blocking vaccine molecule against cutaneous leishmaniasis. East Afr. Med. J.78, 84–63 (2001a).
   PubMedGoogle Scholar
• Tonui WK, Mbati PA, Anjili CO et al. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunization using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in Balb/C mice. East Afr. Med. J.78, 90–92 (2001b).
   Google Scholar
• Saraiva EM, Mendes-Aguiar CO, Paraguai de Souza E et al. The FML-vaccine (Leishmune®) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine24, 2423–2431 (2006).
   Google Scholar
• Travi BL, Tabares CJ, Cadena H et al. Canine visceral leishmaniasis in Colombia: relationship between clinical and parasitologic status and infectivity for sand flies. Am. J. Trop. Med. Hyg.64, 119–224 (2001).
   Google Scholar
• da Costa-Val AP, Cavalcanti RR, de Figueiredo Gontijo N et al. Canine visceral leishmaniasis: relationships between clinical status, humoral immune response, haematology and Lutzomyia (Lutzomyia) longipalpis infectivity. Vet. J.174636–643 (2007).
   Google Scholar
• Titus RG, Bishop JV, Mejia JS. The immunomodulatory factors of arthropod saliva and the potential for these factors to serve as vaccine targets to prevent pathogen transmission. Parasite Immunol.28, 131–41 (2006).
   PubMed Web of Science ®Google Scholar
• Morris RV, Shoemaker CB, David JR, Lanzaro GC, Titus RG. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J. Immunol.167, 5226–5230 (2001).
   PubMed Web of Science ®Google Scholar
• Santos WR, Bernardo RR, Peçanha LT et al. Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani. Vaccine15, 1024–1029 (1997).
   PubMed Web of Science ®Google Scholar
• Takechi M, Tanaka Y. Haemolytic time course differences between steroid and triterpenoid saponins. Planta Med.61, 76–77 (1995).
   PubMed Web of Science ®Google Scholar
• Santos WR, Bernardo RR, Palatnik M et al. Selection of adjuvant for vaccination against experimental kala-azar. The FML antigen of Leishmania donovani in combination with saponin and sapogenin of Bredemeyera floribunda. Mem. Inst. Oswaldo Cruz91, 167 (1996).
   Google Scholar
• Palatnik-de-Sousa CB, Santos WR, Casas CP et al. Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins.Vaccine22, 2470–2479 (2004).
   Google Scholar
• Kensil CR, Patel U, Lennick M et al. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol.146, 431–437 (1991).
   PubMed Web of Science ®Google Scholar
• Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today8, 934–943 (2003).
   PubMed Web of Science ®Google Scholar
• Araújo MS, Andrade RA, Vianna LR et al. Despite Leishvaccine and Leishmune® trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis Vaccine26, 2211–2224 (2008).
   Google Scholar
• da Silva BP, Soares JBRC, Casas CP et al. Pulcherrimasaponin, from the leaves of Calliandra pulcherrima, as adjuvant for visceral leishmaniasis. Vaccine23, 1061–1071 (2005).
   PubMed Web of Science ®Google Scholar
• Nico D, Santos FN, Borja-Cabrera GP et al. Assessment of the monoterpene, glycidic and triterpene-moieties’ contributions to the adjuvant function of the CP05-saponin of Calliandra pulcherrima Benth. Vaccine25, 940, 649–658 (2007).
   Google Scholar
• Nico D, Souza LOP, de Almeida LN et al. Kinins generated upon vaccination with the QS21 saponin-containing Leishmune® vaccine are partially responsible for induction of protective immunity against visceral leishmaniasis. Presented at: The Vaccine Congress. Celebrating 25 Years of Publication. Amsterdam, The Netherlands 9–11 December 2007.
   Google Scholar
• Paraguai de Souza E, Bernardo RR, Palatnik M et al. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine19, 3104–3115 (2001).
   Google Scholar
• Shi W, Schramm VL, Almo SC. Nucleoside hydrolase from Leishmania major Cloning, expression, catalytic properties, transition state inhibitors, and the 2.5-Å crystal structure. J. Biol. Chem.274, 21114–21120 (1999).
   PubMed Web of Science ®Google Scholar
• Gopaul DN, Meyer SL, Degano M et al. Inosine-uridine nucleoside hydrolase from Crithidia fasciculata. Genetic characterization, crystallization, and identification of histidine 241 as a catalytic site residue. Biochemistry35, 5963–5970 (1996).
   PubMed Web of Science ®Google Scholar
• Pellé R, Schramm VL, Parkin DW. Molecular cloning and expression of a purine-specific N-ribohydrolase from Trypanosoma brucei brucei. Sequence, expression and molecular analysis. J. Biol. Chem.273, 2118–2126 (1998).
   Google Scholar
• Mauricio IL, Yeo M, Baghaei M et al. Towards multilocus sequence typing of the Leishmania donovani complex: resolving genotypes and haplotypes for five polymorphic metabolic enzymes (ASAT, GPI, NH1, NH2, PGD). Int. J. Parasitol.36, 757–769 (2006).
   Google Scholar
• Lukes J, Mauricio IL, Schönian G et al. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc. Natl Acad. Sci. USA104, 9375–9380 (2007).
   PubMed Web of Science ®Google Scholar
• Al-Wabel MA, Tonui WK, Cui L et al. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania. Am. J. Trop. Med. Hyg.77, 1060–1065 (2007).
   PubMed Web of Science ®Google Scholar
• Ghazanfari T, Hassan ZM, Ebtekar M et al. Garlic induces a shift in cytokine pattern in Leishmania major-infected Balb/c mice. Scand. J. Immunol.52, 491–495 (2000).
   PubMed Web of Science ®Google Scholar
• Borja Cabrera GP, Santos FN, Miyashiro LM et al. Nucleoside hydrolase DNA vaccine against visceral leishmaniasis. Presented at: The Vaccine Congress. Celebrating 25 Years of Publication. Amsterdam, The Netherlands, 9–11 December 2007.
   Google Scholar